James Underberg at [NYU Langone Medical Center]

James A. Underberg, MD

  • Specialty: Internal Medicine
  • Language: English
  • Phone: 212-726-7430

About Me

Conditions and Treatments

hypocholesterolemia, high cholesterol level, familial hypercholesterolemia, lipid disorders, primary care

Credentials

Positions
  • Clinical Assistant Professor, Department of Medicine
Board Certifications
  • American Board of Internal Medicine - Internal Medicine, 1989
Education and Training
  • Residency, NYU Medical Center, Internal Medicine, 1989
  • MD from University Of Pennsylvania, 1989
Departments

Is this your profile?

Edit profile

Is this your profile?

Edit profile

Locations and Appointments

View Insurance Plans Accepted
  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • MultiPlan/PHCS
    • MultiPlan/PHCS PPO
  • Oxford
    • Oxford Freedom
  • UHC
    • UnitedHealthcare EPO
    • UnitedHealthcare HMO
    • UnitedHealthcare POS
    • UnitedHealthcare PPO
    • UnitedHealthcare Top Tier
Murray Hill Medical Group

317 East 34th St, 7th Fl
New York, NY 10016

Research My Research

Interests

clinical lipidolgy, cholesterol management , inherited lipoprotein disorders

Research Summary

Dr. Underberg maintains an active clinical research program in the field of clinical lipidolgy, cholesterol management and inherited lipoprotein disorders.

Research Interests Timeline

These focus areas and their associated publications are derived from PubMed and the MeSH term library.
represents one publication
Loading...

Publications

  • Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

    Orringer, Carl E; Jacobson, Terry A; Saseen, Joseph J; Brown, Alan S; Gotto, Antonio M; Ross, Joyce L; Underberg, James A Orringer, Carl E; Jacobson, Terry A; Saseen, Joseph J; Brown, Alan S; Gotto, Antonio M; Ross, Joyce L; Underberg, James A
    Journal of clinical lipidology. 2017 May 19. ?-?

  • PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers

    Baum, Seth J; Toth, Peter P; Underberg, James A; Jellinger, Paul; Ross, Joyce; Wilemon, Katherine Baum, Seth J; Toth, Peter P; Underberg, James A; Jellinger, Paul; Ross, Joyce; Wilemon, Katherine
    Clinical cardiology. 2017 Mar 22. 40 (4): 243-254

  • Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels

    Bays, Harold E; Sartipy, Peter; Xu, John; Sjostrom, Carl David; Underberg, James A Bays, Harold E; Sartipy, Peter; Xu, John; Sjostrom, Carl David; Underberg, James A
    Journal of clinical lipidology. 2017 Mar. 11 (2): 450-458.e1

Read All Publications (30)